ViroGates Company Description

ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector.

It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting.

The company’ products icludes suPARnostic TurbiLatex, a latex particle-enhanced turbidimetric immunoassay that quantitatively determines the soluble urokinase plasminogen activator receptor (suPAR) level in human K2-EDTA- or lithium heparin plasma samples; suPARnostic ELISA that provides fully quantitative results; suPARnostic Quick Triage kit, which is used in the point of care situation for early warning and patient triaging that will allow clinicians and nurses to obtain a fast patient prognosis for patient disease severity, progression and outcome; and suPARnostic POC+, a point-of-care finger prick test that detects the level of suPAR in the blood.

The company was founded in 2000 and is headquartered in Birkerød, Denmark.

ViroGates A/S

Country	Denmark
Founded	2000
Industry	Medical Devices
Sector	Healthcare
Employees	10
CEO	Jakob Knudsen

Contact Details

Address: BanevAenget 13 Birkerød, 3460 Denmark
Phone	45 21 13 13 36
Website	virogates.com

Stock Details

Ticker Symbol	VIRO
Exchange	Copenhagen Stock Exchange
Fiscal Year	January - December
Reporting Currency	DKK
ISIN Number	DK0061030574
SIC Code	3845

Key Executives

Name	Position
Jakob Knudsen	Chief Executive Officer
Dr. Jesper Eugen-Olsen	Co-Founder and Chief Scientific Officer
Josephine Baum Jorgensen	Chief Financial Officer
May Britt Dyvelkov	Vice President of Accounting
Thomas Krarup	Vice President of Global Sales and Marketing